Targeting the ERK Pathway: Novel Therapeutics for Thyroid Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1875-5917|4|3|199-220

ISSN： 1568-0088

Source： Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol.4, Iss.3, 2004-01, pp. : 199-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Rb Pathway and Cancer Therapeutics

By  

Current Drug Targets, Vol. 10, Iss. 7, 2009-07 ,pp. : 581-589

Bentham Science Publishers

Access to resources Recommend Favorite

Insights into melanoma: targeting the mTOR pathway for therapeutics

By Pópulo Helena   Soares Paula   Lopes José Manuel  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 7, 2012-07 ,pp. : 689-705

Informa Healthcare

Access to resources Recommend Favorite

Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation

By  

Current Cancer Drug Targets, Vol. 4, Iss. 5, 2004-08 ,pp. : 403-424

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting histone deacetylase in thyroid cancer

By Russo Diego   Durante Cosimo   Bulotta Stefania   Puppin Cinzia   Puxeddu Efisio   Filetti Sebastiano   Damante Giuseppe  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 2, 2013-02 ,pp. : 179-193

Informa Healthcare

Access to resources Recommend Favorite

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors

By  

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 76-86

Bentham Science Publishers

Access to resources Recommend Favorite